TransMedics Group, Inc. (TMDX) Revenue CAGR:30.24%(TTM)
Revenue CAGR uses precomputed financial statement history.
Over longer horizons, TransMedics Group, Inc.'s Revenue CAGR averages 74.74% over 3 years and 90.79% over 5 years.The TTM figure compares the trailing 12 months (sum of the latest four quarters) with the 12 months before that. Rows in the history table compare fiscal years, and the quarterly table compares single quarters; the three measure different windows and will differ. Revenue CAGR measures how TransMedics Group, Inc.'s top-line revenue has grown over time. Consistent revenue growth is a key indicator of business expansion and market share gains.
TMDX Revenue CAGR Chart
TransMedics Group, Inc. (TMDX)
TMDX Quarterly Revenue Growth (YoY)
Revenue growth vs the same quarter one year earlier, last 20 quarters.
TMDX Revenue CAGR History
| Year | Start Revenue | End Revenue | Change | % Change | CAGR |
|---|---|---|---|---|---|
| 2025 | $441.54M | $605.49M | +$163.95M | +37.13% | +37.13% |
| 2024 | $241.62M | $441.54M | +$199.92M | +82.74% | +82.74% |
| 2023 | $93.46M | $241.62M | +$148.16M | +158.53% | +158.53% |
| 2022 | $30.26M | $93.46M | +$63.20M | +208.83% | +208.83% |
| 2021 | $25.64M | $30.26M | +$4.62M | +18.03% | +18.03% |
| 2020 | $23.60M | $25.64M | +$2.04M | +8.62% | +8.62% |
| 2019 | $13.02M | $23.60M | +$10.59M | +81.33% | +81.33% |
| 2018 | $7.68M | $13.02M | +$5.33M | +69.38% | +69.38% |
| 2017 | $6.21M | $7.68M | +$1.48M | +23.77% | +23.77% |
Quarterly Revenue: QoQ & YoY
| Quarter | Value | QoQ | YoY |
|---|---|---|---|
| Q1 2026 | $173.93M | +8.2% | +21.2% |
| Q4 2025 | $160.76M | +11.8% | +32.2% |
| Q3 2025 | $143.82M | -8.6% | +32.2% |
| Q2 2025 | $157.37M | +9.6% | +37.7% |
| Q1 2025 | $143.54M | +18.0% | +48.2% |
| Q4 2024 | $121.62M | +11.8% | +49.8% |
| Q3 2024 | $108.76M | -4.9% | +63.7% |
| Q2 2024 | $114.31M | +18.0% | +117.9% |
| Q1 2024 | $96.85M | +19.3% | +133.1% |
| Q4 2023 | $81.17M | +22.2% | +158.7% |
| Q3 2023 | $66.43M | +26.6% | +158.7% |
| Q2 2023 | $52.47M | +26.3% | +155.7% |
| Q1 2023 | $41.55M | +32.4% | +161.7% |
| Q4 2022 | $31.38M | +22.2% | +224.5% |
| Q3 2022 | $25.68M | +25.2% | +378.3% |
| Q2 2022 | $20.52M | +29.2% | +151.1% |
QoQ = change vs the prior quarter; YoY = change vs the same quarter a year earlier.
About TransMedics Group, Inc.
TransMedics Group, Inc. operates as a commercial-stage medical technology enterprise, committed to transforming the landscape of organ transplant therapy for patients worldwide grappling with end-stage organ failure. At the core of their offerings is the Organ Care System (OCS), an innovative, portable solution engineered to perfuse, optimize, and continuously monitor donor organs. This system leverages exclusive, tailored technology to meticulously recreate near-physiological conditions for these vital organs while they remain outside the human body. The OCS suite encompasses specialized modules: OCS LUNG, which facilitates the preservation of standard criteria donor lungs for double-lung transplants; OCS Heart, designed for the extracorporeal perfusion and maintenance of donor hearts; and OCS Liver, dedicated to the preservation of donor livers. Founded in 1998, TransMedics is headquartered in Andover, Massachusetts.
- Sector
- Healthcare
- Industry
- Medical - Devices
- CEO
- Waleed H. Hassanein